Positive Outlook for Annexon Biosciences Amid Pivotal Studies and Financial Stability
TipRanks (Mon, 13-May 6:47 PM ET)
TipRanks (Mon, 13-May 2:10 PM ET)
TipRanks (Mon, 13-May 11:30 AM ET)
Annexon Biosciences GAAP EPS of -$0.21 beats by $0.12
Seeking Alpha News (Mon, 13-May 8:51 AM ET)
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Globe Newswire (Mon, 13-May 8:00 AM ET)
Annexon Biosciences to Present at the Bank of America Health Care Conference
Globe Newswire (Thu, 9-May 8:00 AM ET)
Globe Newswire (Tue, 7-May 12:30 PM ET)
Globe Newswire (Wed, 1-May 8:00 AM ET)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 16-Apr 4:05 PM ET)
Turnstone Biologics Appoints William Waddill to its Board of Directors
Globe Newswire (Tue, 16-Apr 9:00 AM ET)
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Annexon trades on the NASDAQ stock market under the symbol ANNX.
As of May 13, 2024, ANNX stock price climbed to $4.87 with 1,227,783 million shares trading.
ANNX has a beta of 2.10, meaning it tends to be more sensitive to market movements. ANNX has a correlation of 0.05 to the broad based SPY ETF.
ANNX has a market cap of $443.86 million. This is considered a Small Cap stock.
Last quarter Annexon reported $0 in Revenue and -$.36 earnings per share. This met revenue expectation and exceeded earnings estimates by $.12.
In the last 3 years, ANNX stock traded as high as $24.85 and as low as $1.57.
The top ETF exchange traded funds that ANNX belongs to (by Net Assets): VTI, IWM, VXF, IWN, DWAS.
ANNX has underperformed the market in the last year with a return of -13.7%, while the SPY ETF gained +27.8%. In the last 3 month period, ANNX fell short of the market, returning -10.5%, while SPY returned +4.3%. However, in the most recent 2 weeks ANNX has outperformed the stock market by returning +3.6%, while SPY returned +2.5%.
ANNX support price is $4.48 and resistance is $5.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANNX stock will trade within this expected range on the day.